Analyst Conference Summary

biotechnology

conference date: November 6, 2026 @ 5:00 AM Pacific Time
for quarter ending: September 30, 2026 (third quarter, Q3 2026)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was $ million, down % sequentially from $145 million, and up % from $ million year-earlier.

Net income negative was $ million, up sequentially from negative $782 million, and up from negative $ million year-earlier.

EPS (diluted) was negative $, up sequentially from negative $1.97, and up from negative $ year-earlier.

Guidance:

Conference Highlights:

Stephane Bancel, Moderna's CEO, said ""

Revenue for the quarter was about $ million from the U.S. and $ million international.

In Q3 2026 the norovirus vaccine, mRNA-1403 Phase 3 data did not meet criteria for success at the interim analyis, but is ongoing, with an additional cohort enrolled.

For norovius, the Phase 3 trial of mRNA-1403 is fully enrolled, with data likely in 2026.

In Q3 2026 Moderna presented positive five-year Phase 2b adjuvant melanoma data at the 2026 ASCO Annual Meeting. It showed a sustained benefit with intismeran in combination with Keytruda, reducing the risk of recurrence or death by 49%, compared to Keytruda alone. Phase 3 is fully enrolled. Also has several potential cancer therapies in Phase 1 or Phase 2 or preclinical study.

Moderna's mRNA-3927 for proprionic acidemia registrational trial is fully enrolled. Data likely by the end of 2026.

Cash and investments ended the quarter at $ billion, down sequentially from $6.9 billion. Long-term debt $ million. During the quarter ended Moderna paid $950 million in a litigation settlement.

Operating expense (GAAP) of $ millon consisted of $ million for cost of sales, $ million for R&D, and $ million for SG&A. Operating loss was $ million. $ million interest income; $ million other expense. Income tax $ million.

Q&A Selective Summary:

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: